The Legal Examiner Affiliate Network The Legal Examiner The Legal Examiner The Legal Examiner search feed instagram google-plus avvo phone envelope checkmark mail-reply spinner error close
Skip to main content

Back in 2018, I wrote about the breakthrough that led to Essure rightfully being removed from U.S. markets. I expressed my hope at the time that the women injured by the defective permanent birth control product would one day see the justice they deserve. I’m happy to say that day has come.

Essure was released to market in 2002 by Conceptus, Inc., a company that was bought out by pharmaceutical giant Bayer AG in 2013. In recent years, almost 39,000 claims have been brought against Bayer due to adverse effects in women who have used Essure – reports of persistent pain, perforation of the uterus and fallopian tubes, and migration of the coils into the pelvis or abdomen. Several deaths have also been associated with the device or its related complications.

Following a years-long legal battle that was most recently delayed due to COVID-19, it was finally announced last week that Bayer has agreed to pay $1.6 billion to settle the majority of U.S. claims. Although Bayer maintains that this is not an admission of wrongdoing, this settlement is a major win for plaintiffs in the case. These thousands of women have suffered physical, financial, and psychological strain over the years due to complications caused by the defective device. The settlement monies received by these women will, in my opinion, merely begin to serve the relief owed to them.

Congratulations to lead attorneys Erin Copeland, Fidelma Fitzpatrick, Beth Graham, and Ed Wallace on this incredible coordinated recovery. I applaud your dedication to seeing justice through for those so terribly affected by the Essure defects.

As a settlement planner, I’m always looking to do my part to ensure that justice achieved, lasts a lifetime. To that end, and along with my team at Milestone, I am proud to provide qualified settlement fund administration services to women nationally involved in this litigation.

Comments for this article are closed, but you may still contact the author privately.